VERICEL CORPORATION Shareholders' Equity
VERICEL CORPORATION (VCEL) had Shareholders' Equity of $370.04 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-30
- 2026-06-30: Stockholders' Equity Attributable to Parent $370.04M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $356.23M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $354.64M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $321.86M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $370.04M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $356.23M 10-Q · filed 2026-07-30 |
| 2025-12-31 | $354.64M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $321.86M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $306.81M 10-Q · filed 2026-07-30 |
| 2025-03-31 | $295.49M 10-Q · filed 2026-07-30 |
| 2024-12-31 | $291.97M 10-Q · filed 2026-07-30 |
| 2024-09-30 | $257.47M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $242.98M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $233.90M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $225.95M 10-K · filed 2026-02-26 |
| 2023-09-30 | $204.38M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $198.93M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $193.98M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $192.27M 10-K · filed 2026-02-26 |
| 2022-09-30 | $177.84M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $174.82M 10-Q · filed 2023-11-08 |
| 2022-03-31 | $172.49M 10-Q · filed 2023-11-08 |
| 2021-12-31 | $170.46M 10-K · filed 2025-02-27 |
| 2021-09-30 | $156.78M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $151.09M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $140.21M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $134.26M 10-K · filed 2024-02-29 |
| 2020-09-30 | $114.63M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $107.60M 10-Q · filed 2021-11-09 |
| 2020-03-31 | $110.45M 10-Q · filed 2021-11-09 |
| 2019-12-31 | $111.09M 10-K · filed 2023-02-23 |
| 2019-09-30 | $96.99M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $88.54M 10-Q · filed 2020-11-05 |
| 2019-03-31 | $103.06M 10-Q · filed 2020-11-05 |
| 2018-12-31 | $102.23M 10-K · filed 2022-02-24 |
| 2018-09-30 | $94.47M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $90.60M 10-Q · filed 2019-11-05 |
| 2018-03-31 | $20.93M 10-Q · filed 2019-11-05 |
| 2017-12-31 | $22.54M 10-K · filed 2021-02-24 |
| 2017-09-30 | $16.74M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $13.97M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $15.50M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $24.71M 10-K · filed 2020-02-25 |
| 2016-09-30 | $11.39M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $17.11M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $19.23M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $22.13M 10-K · filed 2019-02-26 |
| 2015-09-30 | $26.41M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $30.24M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $31.70M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $35.64M 10-K · filed 2018-03-05 |
| 2014-09-30 | $37.78M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $2.79M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $3.77M 10-Q · filed 2014-05-15 |
| 2013-12-31 | $3.89M 10-K · filed 2017-03-13 |
| 2013-09-30 | $4.95M 10-Q · filed 2013-11-12 |
| 2013-06-30 | -$41.03M 10-Q · filed 2013-08-07 |
| 2013-03-31 | -$36.57M 10-Q · filed 2013-05-08 |
| 2012-12-31 | -$32.10M 10-K · filed 2015-03-25 |
| 2012-09-30 | -$24.64M 10-Q · filed 2012-11-08 |
| 2012-06-30 | -$20.71M 10-Q · filed 2012-08-07 |
| 2012-03-31 | -$21.72M 10-Q · filed 2012-05-10 |
| 2011-12-31 | -$12.97M 10-K · filed 2014-03-13 |
| 2011-09-30 | -$11.16M 10-Q · filed 2011-11-08 |
| 2011-06-30 | -$10.16M 10-Q · filed 2011-08-15 |
| 2010-12-31 | $2.92M 10-K · filed 2014-03-13 |
| 2010-06-30 | $14.78M 10-K · filed 2013-03-18 |
| 2009-06-30 | $16.75M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |